X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ASTRAZENECA PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS ASTRAZENECA PHARMA IPCA LABS/
ASTRAZENECA PHARMA
 
P/E (TTM) x 28.6 159.7 17.9% View Chart
P/BV x 3.4 24.8 13.7% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
ASTRAZENECA PHARMA
Mar-14
IPCA LABS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,285 54.1%   
Low Rs400634 63.1%   
Sales per share (Unadj.) Rs260.2189.6 137.2%  
Earnings per share (Unadj.) Rs19.0-0.2 -9,318.0%  
Cash flow per share (Unadj.) Rs33.13.8 859.8%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.068.6 310.4%  
Shares outstanding (eoy) m126.2025.00 504.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.15.1 41.6%   
Avg P/E ratio x28.9-4,712.7 -0.6%  
P/CF ratio (eoy) x16.6249.6 6.6%  
Price / Book Value ratio x2.614.0 18.4%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,12023,988 288.1%   
No. of employees `00013.31.6 850.2%   
Total wages/salary Rs m7,3591,605 458.6%   
Avg. sales/employee Rs Th2,477.43,040.2 81.5%   
Avg. wages/employee Rs Th555.21,029.2 53.9%   
Avg. net profit/employee Rs Th180.6-3.3 -5,532.8%   
INCOME DATA
Net Sales Rs m32,8364,740 692.8%  
Other income Rs m41892 453.9%   
Total revenues Rs m33,2544,832 688.2%   
Gross profit Rs m4,505-130 -3,470.6%  
Depreciation Rs m1,777101 1,756.2%   
Interest Rs m2400-   
Profit before tax Rs m2,905-139 -2,091.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m5115 10,041.3%   
Profit after tax Rs m2,394-5 -47,037.3%  
Gross profit margin %13.7-2.7 -501.0%  
Effective tax rate %17.6-3.7 -480.1%   
Net profit margin %7.3-0.1 -6,789.7%  
BALANCE SHEET DATA
Current assets Rs m19,4552,726 713.6%   
Current liabilities Rs m10,0762,435 413.8%   
Net working cap to sales %28.66.1 464.6%  
Current ratio x1.91.1 172.4%  
Inventory Days Days9874 132.7%  
Debtors Days Days6741 164.2%  
Net fixed assets Rs m20,2601,035 1,956.9%   
Share capital Rs m25250 504.8%   
"Free" reserves Rs m26,633942 2,826.1%   
Net worth Rs m26,8861,716 1,566.8%   
Long term debt Rs m2,3400-   
Total assets Rs m41,1734,156 990.7%  
Interest coverage x13.1NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.81.1 69.9%   
Return on assets %6.4-0.1 -5,224.3%  
Return on equity %8.9-0.3 -3,002.2%  
Return on capital %10.80-  
Exports to sales %47.65.7 835.6%   
Imports to sales %14.96.5 230.1%   
Exports (fob) Rs m15,642270 5,789.1%   
Imports (cif) Rs m4,884306 1,594.4%   
Fx inflow Rs m15,642375 4,175.7%   
Fx outflow Rs m4,884470 1,038.7%   
Net fx Rs m10,759-96 -11,259.5%   
CASH FLOW
From Operations Rs m3,411-8 -42,114.8%  
From Investments Rs m-1,354-146 929.3%  
From Financial Activity Rs m-1,304862 -151.3%  
Net Cashflow Rs m753709 106.3%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 15.7 161.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 12,856 287.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  PLETHICO PHARMA  MERCK LTD  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 13, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS